Thyroid Eye Disease (TED) is an organ-specific autoimmune disease closely associated with thyroid disorders. Patients face not only the risks of exophthalmos, diplopia, eye pain, vision loss and even blindness, but also psychological problems such as anxiety and social barriers caused by facial changes. Traditional treatments have limited efficacy or side effect risks, creating an urgent need for safer and more effective innovative therapies to break through the dilemma.
In recent years, with the deepening of TED-related research and the clinical development of novel targeted drugs, new hope has emerged for the treatment of TED. In particular, the launch of Tiptozumab N01 Injection – the first domestically developed targeted drug against insulin-like growth factor-1 receptor (IGF-1R) – marks that TED treatment has entered the era of precision targeting.
In early 2025, Tiptozumab N01 Injection, an innovative drug developed by Innovent Biologics, was approved for the treatment of thyroid eye disease and has since been widely used in China. After receiving treatment with Tiptozumab N01 Injection, many patients achieved regression of exophthalmos, resolution of inflammation, improvement in diplopia, enhanced visual function and significant cosmetic improvement.
Clinically, many patients are initially unaware of hyperthyroidism or hypothyroidism until ocular symptoms occur, and thyroid abnormalities are only detected during ophthalmic consultation.
Tiptozumab marks that thyroid eye disease treatment has entered a genuine “era of accessibility”. It has not only significantly reduced treatment costs, but also enabled more patients to receive timely, effective and safe targeted drugs, realizing a critical leap from “having access to medicine” to “being able to afford it”.